Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2002 1
2003 2
2004 3
2005 1
2006 1
2008 1
2009 6
2010 4
2011 4
2012 3
2013 3
2014 2
2015 1
2016 8
2017 7
2018 11
2019 15
2020 14
2021 15
2022 5
2023 7
2024 10
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Cytokine release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma.
Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, Luan D, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Elsawy M, Ganguly S, Geethakumari PR, Greenbaum U, Hashmi H, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, Mead E, McGuirk JP, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Riedell PA, Saber W, Mirza AS, Magalhaes-Silverman M, Shpall EJ, Sorror M, Wudhikarn K, Turtle CJ, Moskop A, Pasquini MC. Shouval R, et al. Among authors: turtle cj. Transplant Cell Ther. 2025 Apr 25:S2666-6367(25)01100-5. doi: 10.1016/j.jtct.2025.03.011. Online ahead of print. Transplant Cell Ther. 2025. PMID: 40288610
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up.
Tuazon SA, Portuguese AJ, Pont MJ, Cowan AJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake ML, Works MG, Shadman M, Liang EC, Wu Q, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Riddell SR, Green DJ. Tuazon SA, et al. Among authors: turtle cj. Blood. 2025 Apr 8:blood.2024027681. doi: 10.1182/blood.2024027681. Online ahead of print. Blood. 2025. PMID: 40198877
Cytokine-mediated increase in endothelial-leukocyte interaction mediates brain capillary plugging during CAR T cell neurotoxicity.
Park L, Tsai YT, Lim HK, Faulhaber LD, Burleigh K, Faulhaber EM, Bose M, Shih AY, Hirayama AY, Turtle CJ, Annesley CE, Gardner RA, Gustafson HH, Gust J. Park L, et al. Among authors: turtle cj. bioRxiv [Preprint]. 2025 Feb 25:2025.02.19.638920. doi: 10.1101/2025.02.19.638920. bioRxiv. 2025. PMID: 40060404 Free PMC article. Preprint.
Protection of CD33-modified hematopoietic stem cell progeny from CD33-directed CAR T cells in nonhuman primates.
Petty NE, Radtke S, Kanestrom G, Fields E, Humbert O, Fiorenza S, Llewellyn MJ, Laszlo GS, Thomas J, Burger Z, Swing K, Zhu H, Jerome KR, Turtle CJ, Walter RB, Kiem HP. Petty NE, et al. Among authors: turtle cj. Blood Adv. 2025 Feb 10:bloodadvances.2024015016. doi: 10.1182/bloodadvances.2024015016. Online ahead of print. Blood Adv. 2025. PMID: 39928955
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.
Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ. Landsburg DJ, et al. Among authors: turtle cj. J Immunother Cancer. 2025 Feb 9;13(2):e009890. doi: 10.1136/jitc-2024-009890. J Immunother Cancer. 2025. PMID: 39924174 Free PMC article.
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL.
Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, Voutsinas JM, Wu QV, Jaeger-Ruckstuhl CA, Pender BS, Kirchmeier DR, Torkelson A, Braathen K, Basom R, Shadman M, Kopmar NE, Cassaday RD, Riddell SR, Maloney DG, Turtle CJ. Gauthier J, et al. Among authors: turtle cj. Blood Adv. 2025 Apr 22;9(8):1861-1872. doi: 10.1182/bloodadvances.2024015314. Blood Adv. 2025. PMID: 39820359 Free PMC article. Clinical Trial.
High-dimensional data bridges for CARs.
Fiorenza S, Turtle CJ. Fiorenza S, et al. Among authors: turtle cj. Blood. 2024 Dec 12;144(24):2463-2464. doi: 10.1182/blood.2024026564. Blood. 2024. PMID: 39666333 No abstract available.
Development and validation of predictive models of early immune effector cell-associated hematotoxicity.
Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu Q, Torkelson A, Kirchmeier D, Chutnik A, Pender B, Sorror M, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green D, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J. Liang EC, et al. Among authors: turtle cj. Blood Adv. 2025 Feb 11;9(3):606-616. doi: 10.1182/bloodadvances.2024014455. Blood Adv. 2025. PMID: 39626349 Free PMC article.
120 results